Abeona Granted Licenses to Develop Gene Therapies for Four Rare Disorders

Abeona Therapeutics was granted new exclusive licenses to develop gene therapies for treatment of four rare lysosomal storage disorders using REGENXBIO’s NAV AAV9 vector platform technology.